$エッジワイズ セラピューティックス(EWTX.US)$ NEWS Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy. Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten. Sevasemten was...
The considerable share sell-off by Co-Founder and low insider ownership at Edgewise Therapeutics may indicate disalignment with shareholders. This could suggest a lack of confidence in its future performance.
Edgewise Therapeutics' rising cash burn signals concern. Shareholders could experience costly dilution if the company sells shares to fund another year's growth. It's advised for shareholders to keep a close eye on the company's cash burn.
エッジワイズ セラピューティックスに関するコメント
NEWS
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was...
まだコメントはありません